Mereo BioPharma Group PLC is a biopharmaceutical company that creates and distributes treatments for rare diseases and oncology. Their products are in various clinical trial phases, including etigilimab, which is in phase 1b. Mereo BioPharma Group PLC has offices in London and works with The University of Texas MD Anderson Cancer Center.